An unbranded injection pen on a linen cloth next to a glass of water

CagriSema in Women: 25% Weight Loss Across Menopause Stages


Women in Novo Nordisk’s big CagriSema trial lost 25.0% of their body weight on average after 68 weeks, versus 3.0% on placebo, according to two new analyses presented on October 20, 2026 at The Menopause Society annual meeting in San Diego. The results held up across menopause stages, from 26.7% before menopause to 23.1% after it. The honest fine print: these are after-the-fact (post hoc) analyses using a best-case way of counting, and CagriSema is still not FDA-approved, with a decision expected in Q4 2026.

Key facts

What is CagriSema, quickly?

CagriSema is a once-weekly injection that combines two peptides: semaglutide, the GLP-1 medicine in Wegovy, and cagrilintide, a long-acting copy of amylin, a hormone released with insulin that helps signal fullness after meals. We covered the main trials and the September EASD data in our CagriSema 2026 overview. This post is only about the new results in women.

What did the new analyses find?

Novo ran two analyses of women in REDEFINE 1.

Analysis 1: all women. The trial included groups on CagriSema, on each of its two parts alone, and on placebo. That lets you see what the pairing adds:

Group (women) Weight change at 68 weeks Waist change Lost 20% or more
CagriSema 2.4 / 2.4 mg (1,441) -25.0% -20.5 cm 68.7%
Semaglutide 2.4 mg alone (199) -19.0% -17.4 cm 38.0%
Cagrilintide 2.4 mg alone (208) -13.4% -11.7 cm 17.9%
Placebo (461) -3.0% -4.7 cm 1.8%

Average starting weight was about 100 to 102 kg (roughly 220 to 225 lb) in every group. On CagriSema, 93.3% of women lost at least 10% of their body weight.

Analysis 2: by menopause stage. Among 1,902 women grouped by stage, average weight loss on CagriSema was 26.7% in premenopausal women (408 on CagriSema), 24.8% in perimenopausal women (256) and 23.1% in postmenopausal women (530). Placebo groups lost under 3% at every stage. Women on hormone therapy were analyzed separately.

Why menopause is the interesting part

A lot of women gain weight as they move through menopause, which is the reason Novo gave for looking at this. Here, results were strong at every stage. Weight loss was a bit lower after menopause, but still above 23% on average. The study’s lead author, Maria D. Hurtado Andrade of Mayo Clinic, said the numerical differences between groups “highlight the need for further research” on how reproductive aging affects weight loss.

The fine print, told plainly

Good results, but read them for what they are:

How does it compare?

Inside this trial, CagriSema beat semaglutide alone in women by about 6 percentage points (25.0% vs 19.0%), which is the clearest sign the amylin half adds something. Comparing with other drugs’ trials is trickier, because populations and counting methods differ. For context on the approved weekly shots, see semaglutide vs tirzepatide. Lilly is testing its own amylin pairing too, covered in our EloraTZP results.

When could CagriSema be available?

Novo filed with the FDA in December 2025 and expects a decision in Q4 2026. Until then, CagriSema is investigational: it is only available inside clinical trials, and there is no approved compounded version. Anything sold online as “CagriSema” today is not an approved product. For where unapproved peptides stand legally, see our legal status tracker.

What it means for you

This is good news for women with obesity, including those going through or past menopause: one of the next weekly options looks strong at every stage, and an FDA decision is close. It is not approved yet, these specific numbers come from exploratory analyses, and the stomach side effects are real. Women curious about it can talk to a licensed provider about the approved options available today and about whether a clinical trial or a future approval might fit. Our GLP-1 price tracker helps compare the approved options.

Sources

Educational content only, not medical advice. Talk to a licensed provider about whether any medicine is right for you.

← All articles